Bis-choline tetrathiomolybdate - Wilson Therapeutics

Drug Profile

Bis-choline tetrathiomolybdate - Wilson Therapeutics

Alternative Names: ATN-224; Decuprate; WTX-101

Latest Information Update: 01 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Attenuon LLC
  • Developer Attenuon; Cancer Research UK; Wilson Therapeutics
  • Class Antineoplastics; Heavy metals; Neuroprotectants; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatolenticular degeneration
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatolenticular degeneration
  • Discontinued Breast cancer; Malignant melanoma; Multiple myeloma; Prostate cancer; Solid tumours

Most Recent Events

  • 01 Aug 2017 Discontinued - Phase-II for Breast cancer (Combination therapy, Late-stage disease) in United Kingdom (PO)
  • 21 Apr 2017 Preliminary efficacy, pharmacokinetic and adverse events data from a phase II trial in Wilson's disease presented at the 69th annual meeting of the American Academy of Neurology (AAN-2017)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top